0.000340196956132595 0.000429722470904224 0.000250671441360763 -0.00173679498657122 0.00211280214861247 0.000537153088630382 0.00211280214861247 0.00211280214861247
Sign Up Today X
Thanks for submitting the form.
Stockreport

For Colon Cancer That No Longer Responds to Treatment, A New Drug Combination Offers Hope [Yahoo! Finance]

Amgen Inc. (AMGN)  More Company Research Source: Yahoo! Finance
Last amgen inc. earnings: 4/30 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.amgen.com
LOS ANGELES, April 24, 2025 BUSINESS WIRE )--A novel combination therapy offers better outcomes for patients with KRAS G12C metastatic colorectal cancer that have stopped responding to chemotherapy, according to a Phase 3 clinical trial by researchers at City of Hope ® , one of the largest and most advanced cancer research and treatment organizations in the U.S., with its National Medical Center named top 5 in the nation for cancer care by U.S. News & World Report. The Food and Drug Administration (FDA) in January approved the combination to treat patients with metastatic KRAS G12C mutated colorectal cancer that has progressed following chemotherapy. In a new study published in the Journal of Clinical Oncology, colorectal cancer patients who received a combination of two drugs, small molecule KRAS G12C inhibitor sotorasib combined with monoclonal antibody panitumumab, had significantly longer progression-free survival compared to those who received standard of care. Researchers als [Read more]
IMPACT SNAPSHOT EVENT TIME: AMGN
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
AMGN alerts
from News Quantified
AMGN
NEWS
AMGN
Earnings
AMGN
Analyst Actions
AMGN
SEC Filings
Stockreport

For Colon Cancer That No Longer Responds to Treatment, A New Drug Combination Offers Hope [Yahoo! Finance]

Amgen Inc.  (AMGN) 
More Company Research Source: Yahoo! Finance
Last amgen inc. earnings: 4/30 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.amgen.com
LOS ANGELES, April 24, 2025 BUSINESS WIRE )--A novel combination therapy offers better outcomes for patients with KRAS G12C metastatic colorectal cancer that have stopped responding to chemotherapy, according to a Phase 3 clinical trial by researchers at City of Hope ® , one of the largest and most advanced cancer research and treatment organizations in the U.S., with its National Medical Center named top 5 in the nation for cancer care by U.S. News & World Report. The Food and Drug Administration (FDA) in January approved the combination to treat patients with metastatic KRAS G12C mutated colorectal cancer that has progressed following chemotherapy. In a new study published in the Journal of Clinical Oncology, colorectal cancer patients who received a combination of two drugs, small molecule KRAS G12C inhibitor sotorasib combined with monoclonal antibody panitumumab, had significantly longer progression-free survival compared to those who received standard of care. Researchers als [Read more]
IMPACT SNAPSHOT
EVENT TIME:
AMGN
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Don't Miss Out On The Next BIG Stock Move
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS